Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient has completed the Week 24 visit procedures of Study FKB327-002 (NCT02260791) and are continuing with methotrexate~2. In the investigator's opinion, the patient showed a clinical response to treatment during Study FKB327-002 (NCT02260791)~Exclusion Criteria:~1. Patient has evidence of a serious adverse event (SAE) ongoing from Study FKB327-002~2. Patient has presence of active and/or untreated latent tuberculosis (TB)~Other Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FKB327 (Type: EXPERIMENTAL): Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.
- Humira® (Type: ACTIVE_COMPARATOR): Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).